Christian Antoni, MD, Friedrich-Alexander University, Erlangen, Germany; Arthur Kavanaugh, MD, University of California, San Diego, Division of Rheumatology, Allergy, and Immunology, La Jolla, CA, United States; Cythia Guzzo, MD, Centocor, Inc., Malvern, PA, United States; Gerald Krueger, MD, University of Utah Health Sciences Center, Salt Lake City, UT, United StatesLe texte complet de cet article est disponible en PDF.
Dr. Antoni is an investigator and consultant for infliximab at Centocor, Inc. Dr. Kavanaugh has consulted for and participated in clinical research sponsored by Centocor, Amgen Inc., and Abbott Laboratories. Dr. Krueger is a consultant to Biogen, Genentech, and Centocor; on the sponsored speakers list for Amgen, Biogen, Genentech, and Centocor; and have participated in clinical trials for each of these companies. Neither Dr. Krueger nor his family owns stock in these companies.
Studies have been funded by research grant from Centocor (IMPACT) or have been done by Centocor (IMPACT 2).